Persantine

cardiac valve replacement, Ischemic Attack, Transient, Coronary Disease + 9 more

Treatment

6 FDA approvals

12 Active Studies for Persantine

What is Persantine

Dipyridamole

The Generic name of this drug

Treatment Summary

Dipyridamole is a drug that works by inhibiting an enzyme called phosphodiesterase. This prevents the absorption and breakdown of a molecule called adenosine, which helps to reduce blood clotting and improve the production of a hormone-like substance called prostacyclin.

Dipyridamole

is the brand name

Persantine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Dipyridamole

Dipyridamole

1980

98

Approved as Treatment by the FDA

Dipyridamole, also known as Dipyridamole, is approved by the FDA for 6 uses like Postoperative Thromboembolism and cardiac valve replacement .

Postoperative Thromboembolism

cardiac valve replacement

Venous Thrombosis

Stroke

Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid

Stroke

Used to treat previous stroke in combination with Acetylsalicylic acid

Transient Ischemic Attack (TIA)

Used to treat Transient Ischemic Attack in combination with Acetylsalicylic acid

Effectiveness

How Persantine Affects Patients

Dipyridamole is a drug used to open up blood vessels and stop blood clots from forming. It is often taken in combination with other medicines, such as warfarin, to help prevent stroke in people with heart or vascular problems. Dipyridamole is also used to take pictures of the heart's blood flow, to prevent blood clots from forming, and in combination with aspirin to help avoid stroke.

How Persantine works in the body

Dipyridamole works to stop blood clotting by preventing the breakdown of molecules that inhibit platelet function. It also increases the production of a molecule called prostacyclin, which stops platelets from clumping together and forming a clot.

When to interrupt dosage

The suggested measure of Persantine is dependent upon the diagnosed affliction, such as Thrombosis, preceding stroke, and Stroke. The amount of dosage fluctuates, in line with the administration approach (e.g. Tablet, coated or Capsule) presented in the table below.

Condition

Dosage

Administration

cardiac valve replacement

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Ischemic Attack, Transient

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Coronary Disease

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Stroke

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Heart Valve Prosthesis

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Myocardial Perfusion Imaging

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Venous Thrombosis

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Anti-platelet Therapy

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Ischemic Stroke

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Stroke

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Diagnostic Imaging

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Transient Ischemic Attack (TIA)

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Warnings

Persantine has three contraindications and should not be amalgamated with any of the conditions listed in the table below.

Persantine Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Atrioventricular Block

Do Not Combine

Respiratory Sounds

Do Not Combine

There are 20 known major drug interactions with Persantine.

Common Persantine Drug Interactions

Drug Name

Risk Level

Description

Abrocitinib

Major

The risk or severity of bleeding and thrombocytopenia can be increased when Dipyridamole is combined with Abrocitinib.

Acebutolol

Major

Dipyridamole may increase the bradycardic activities of Acebutolol.

Albutrepenonacog alfa

Major

The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dipyridamole.

Alprenolol

Major

Dipyridamole may increase the bradycardic activities of Alprenolol.

Alprostadil

Major

The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.

Persantine Toxicity & Overdose Risk

Low blood pressure can be a short-term side effect of this drug, but medication to raise blood pressure can be used if needed. Toxic levels of this drug in rats are higher than 6,000 mg/kg, while in dogs it is approximately 400 mg/kg. The lethal dose for rats is 8.4 g/kg when taken orally.

Persantine Novel Uses: Which Conditions Have a Clinical Trial Featuring Persantine?

38 active clinical trials are presently exploring the potential of Persantine to reduce Postoperative Thromboembolism, Stroke and Thrombosis.

Condition

Clinical Trials

Trial Phases

Coronary Disease

1 Actively Recruiting

Not Applicable

Venous Thrombosis

0 Actively Recruiting

cardiac valve replacement

0 Actively Recruiting

Heart Valve Prosthesis

0 Actively Recruiting

Transient Ischemic Attack (TIA)

2 Actively Recruiting

Phase 4, Not Applicable

Diagnostic Imaging

0 Actively Recruiting

Ischemic Stroke

2 Actively Recruiting

Not Applicable

Ischemic Attack, Transient

0 Actively Recruiting

Anti-platelet Therapy

0 Actively Recruiting

Stroke

0 Actively Recruiting

Stroke

6 Actively Recruiting

Not Applicable, Phase 1

Myocardial Perfusion Imaging

1 Actively Recruiting

Phase 1

Persantine Reviews: What are patients saying about Persantine?

5

Patient Review

6/28/2010

Persantine for Transient Ischemic Attack

It's been 16 months since I had a TIA, so this treatment is definitely working. The only downside is that I experience quite a bit of muscle pain/cramping in my legs; however, that is a small price to pay for avoiding another attack.

5

Patient Review

8/8/2009

Persantine for Myocardial Reinfarction Prevention

This was prescribed following a stroke and I had a blood clot located in a crucial spot in the brain. I cannot tolerate Coumadin and this drug works wonders for me!

5

Patient Review

9/25/2008

Persantine for Transient Ischemic Attack

I've been making great progress with my treatment thanks to this medication.

5

Patient Review

10/3/2012

Persantine for Prevention for a Blood Clot going to the Brain

No issues with the product itself, though I did find the container difficult to open.

3

Patient Review

4/26/2014

Persantine for Transient Ischemic Attack

I'm not sure if this is the cause, but I've developed some pretty severe arthritis and weakness in my calf muscles since taking this medication. It's gotten to the point where I can't stand or walk.

2.3

Patient Review

1/11/2009

Persantine for Transient Ischemic Attack

The side effects of this drug were really tough for me to get used to, so I stopped taking it.

2.3

Patient Review

12/14/2008

Persantine for Transient Ischemic Attack

I felt dizzy, had neck aches and headaches. I also felt weak overall.

1

Patient Review

10/11/2013

Persantine for Transient Ischemic Attack

This made my calves feel really tight, like they weren't getting enough oxygen. It was tough to walk around at all while taking this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about persantine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are side effects of Persantine?

"Common side effects of the medication include dizziness, stomach upset, diarrhea, vomiting, headache, and flushing. These side effects are usually mild and resolve over time as your body adjusts to the medication."

Answered by AI

Is Persantine still available?

"Boehringer Ingelheim Pharmaceuticals has announced the permanent discontinuation of Persantine (dipyridamole) tablets. The decision to discontinue the product is business-related and not due to product safety or efficacy."

Answered by AI

What is a Persantine injection?

"Dipyridamole is used to prevent blood clots after heart valve replacement surgery. It is also given as part of a test that shows how well your heart is pumping blood."

Answered by AI

What is the drug Persantine used for?

"It helps prevent blood clots by keeping platelets from sticking together.

Dipyridamole is a medication used to prevent the formation of blood clots. It is often used in combination with other medications, such as warfarin, to keep clots from forming after heart valve replacements. Clots are a serious complication that can cause strokes, heart attacks, or blocked blood vessels in the lungs (pulmonary embolisms). Dipyridamole works by keeping platelets from sticking together."

Answered by AI

Clinical Trials for Persantine

Image of University of Michigan in Ann Arbor, United States.

Brain Stimulation for Stroke and Aphasia

18+
All Sexes
Ann Arbor, MI

The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is: * Does transcranial direct current stimulation (tDCS) administered to the pre-frontal areas of the brain improve post-stroke fatigue and aphasia? * What kinds of participant characteristics are associated with better improvement of post-stroke fatigue and aphasia? Researchers will compare active electrical stimulation to sham stimulation to see if the active stimulation does a better job at reducing fatigue and language deficits after stroke. Participants will be asked to complete fatigue, language, and cognitive testing before and after receiving 10 sessions of tDCS plus speech and language therapy.

Recruiting
Device

University of Michigan (+1 Sites)

Image of Kessler Foundation in West Orange, United States.

Robotic Balance Training + Brain Stimulation for Stroke

18 - 75
All Sexes
West Orange, NJ

Our proposed study, "NEUROBALANCE Stroke,"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before enrolment and experience persistent balance and gait deficits. Participants will be randomized into three groups: (1) robotic balance training with active brain stimulation, (2) robotic balance training with sham brain stimulation, and (3) standard-of-care rehabilitation. The study will involve 15 training sessions over 5 weeks, with assessments conducted at baseline, post-training, and two months post-training to evaluate balance recovery and retention. The primary focus is understanding how this intervention affects brain and muscle activity during balance tasks and how these changes translate into functional improvements in clinical outcome measures of balance function. Additionally, participant feedback on brain stimulation and exercise engagement will be collected to inform future studies. The findings may guide the development of personalized training protocols and contribute to broader rehabilitation strategies.

Recruiting
Device

Kessler Foundation

Vikram Shenoy Handiru,, PhD

Image of Brooks Rehabilitation Clinical Research Center in Jacksonville, United States.

Q Therapeutic System for Stroke

18 - 80
All Sexes
Jacksonville, FL

This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.

Recruiting
Has No Placebo

Brooks Rehabilitation Clinical Research Center

Emily Fox, PT, DPT, MHS, PhD

BrainQ Technologies Ltd.

Have you considered Persantine clinical trials?

We made a collection of clinical trials featuring Persantine, we think they might fit your search criteria.
Go to Trials

Have you considered Persantine clinical trials?

We made a collection of clinical trials featuring Persantine, we think they might fit your search criteria.
Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Low SAR MRI Scans for Coronary Heart Disease

18 - 100
All Sexes
Bethesda, MD

Background: Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with metal devices in their body, or in invasive heart procedures using metal tools. Objective: To test a new MRI scanner and software changes to create better pictures. Eligibility: People with disease and healthy volunteers, ages 18 and older. Design: Participants will be screened with blood tests. Participants may have both the new MRI and a conventional MRI or only the new one. If 2 are done, they must be within 60 days. For both MRI versions, participants lie on a table that slides into a large tube. During scans, they will hold their breath for up to 20 seconds at a time. Heart activity will be measured by wires connected to pads on the skin. A flexible belt may be used to monitor their breathing. They will be in the scanner up to 2 hours. Participants can agree to have a dye called gadolinium injected into their arm during the scan. This brightens the pictures. Participants can agree to take a drug called a vasodilator. This helps detect areas of the heart with abnormal blood supply. Scans of the heart are taken before, during, and after they get the medicine. The drug may cause temporary chest pain or shortness of breath. They may get other drugs to relieve these symptoms. Sponsoring Institution: National Heart, Lung, and Blood Institute

Recruiting
Has No Placebo

National Institutes of Health Clinical Center

Adrienne E Campbell, Ph.D.